Effects of Pravastatin Sodium Alone and in Combination with Cholestyramine on Hepatic, Intestinal and Adrenal Low Density Lipoprotein Receptors in Homozygous Watanabe Heritable Hyperlipidemic Rabbits

• Published in: Japanese journal of pharmacology Vol. 59; no. 1; pp. 65 - 70
• Main Authors: Kuroda, Masao, Matsumoto, Akiyo, Itakura, Hiroshige, Watanabe, Yoshio, Ito, Takashi, Shiomi, Masashi, Fukushige, Junichiro, Nara, Futoshi, Fukami, Masaharu, Tsujita, Yoshio
• Format: Journal Article
• Language: English
• Published: Kyoto The Japanese Pharmacological Society 1992; Japanese Pharmacological Society
• Subjects: Adrenal Glands - drug effects; Adrenal Glands - metabolism; Animals; Biological and medical sciences; Cholesterol, LDL - blood; Cholestyramine; Cholestyramine Resin - pharmacology; Drug Synergism; General and cellular metabolism. Vitamins; HMG-CoA reductase inhibitor; Hyperlipidemias - genetics; Hyperlipidemias - metabolism; Intestinal Mucosa - metabolism; Intestines - drug effects; LDL receptor; Liver - drug effects; Liver - metabolism; Male; Medical sciences; Pharmacology. Drug treatments; Pravastatin; Pravastatin - pharmacology; Rabbits; Receptors, LDL - genetics; Receptors, LDL - metabolism; RNA, Messenger - analysis; WHHL rabbits; WHHL rabbits; Cholestyramine; Pravastatin; HMG-CoA reductase inhibitor; LDL receptor; Animal model; Enzyme; Enzyme inhibitor; Rabbit; Metabolic diseases; Lipids; Lagomorpha; Cholesterol; Lipoprotein LDL; Vertebrata; Chemotherapy; Mammalia; Treatment; Animal; Hydroxymethylglutaryl-CoA reductase; Hyperlipemia; Organ specificity; Antilipemic agent; Biological receptor
• ISSN: 0021-5198; 1347-3506
• DOI: 10.1254/jjp.59.65

Pravastatin sodium (pravastatin), a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, was administered alone (50 mg/kg) or in combination with cholestyramine, a bile acid sequestrant resin, at the level of 2% in the diet to homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits for 4 weeks. The low density lipoprotein (LDL)-cholesterol levels were reduced by 29% and 56% with pravastatin alone and the combination treatment, respectively. Hepatic LDL receptor activity was increased by 11.2- and 13.9-fold with pravastatin alone and the combination treatment, respectively. The LDL receptor activity in the untreated homozygous WHHL rabbits was only 2.5% of that in the normal rabbits. mRNA for the LDL receptor in the liver was also increased by 2.1- and 3.4-fold with pravastatin alone and the combination treatment, respectively. On the other hand, mRNA for the LDL receptor in the adrenal gland was not affected by pravastatin and the combination treatment, whereas the mRNA in the intestine was increased in both groups. These results suggest the following: 1) the induction of hepatic LDL receptor activity by the treatment of pravastatin alone or in combination with cholestyramine is the main cause of the reduction of serum cholesterol levels by these treatments even in LDL receptor-deficient animals. 2) The induction of the mRNA for the LDL receptor in the liver and intestine, but not that in the adrenal gland, might be a reflection of the tissue-selective inhibition of cholesterol synthesis by pravastatin.